Ventibag home-use “smart” ventilator harvests oxygen from the air

It’s an unfortunate fact that people with severe respiratory illnesses are often confined to hospitals, where they must breathe through ventilators. A new portable device that harvests oxygen from the air, however, may someday allow them to stay at hom… Continue reading Ventibag home-use “smart” ventilator harvests oxygen from the air

Pfizer’s COVID vaccine remains 100% effective in kids after four months

New follow-up data from Pfizer’s Phase 3 trial testing its mRNA COVID-19 vaccine in 12 to 15 year olds show robust efficacy up to four months after the two-dose protocol. The data reveals the vaccine is 100 percent effective at preventing symptomatic S… Continue reading Pfizer’s COVID vaccine remains 100% effective in kids after four months

All US adults now eligible for third dose of COVID-19 vaccine

US regulators have authorized a third COVID-19 vaccine booster dose for all adults over the age of 18. The new recommendations simplify the health advice and infectious disease expert Anthony Fauci urges boosters for all those who are six months beyond… Continue reading All US adults now eligible for third dose of COVID-19 vaccine

Real-world data finds 3rd COVID vaccine dose greatly boosts protection

New real-world data from the UK Health Security Agency has shown a third COVID-19 vaccine dose significantly boosts protection against symptomatic disease. The findings indicate a third dose will be vital in pushing back the growing wave of SARS-CoV-2 … Continue reading Real-world data finds 3rd COVID vaccine dose greatly boosts protection

India’s Covaxin COVID-19 vaccine 77.8% effective, Lancet study finds

A new study in The Lancet is offering the first peer-reviewed and published data on the efficacy of Covaxin, a COVID-19 vaccine developed in India. The vaccine was found to be 77.8 percent effective at preventing symptomatic COVID-19 in a large Phase 3… Continue reading India’s Covaxin COVID-19 vaccine 77.8% effective, Lancet study finds

Experimental RNA therapy harnesses immune system to fight COVID-19

Researchers at the Yale School of Medicine have developed a new kind of COVID-19 treatment designed to stimulate the body’s immune defenses and fight off a coronavirus infection at its earliest stages. In preclinical animal tests an experimental RNA mo… Continue reading Experimental RNA therapy harnesses immune system to fight COVID-19

Majority of Americans believe at least some form of COVID misinformation

A new survey from the Kaiser Family Foundation (KFF) has found 78 percent of Americans believe at least one piece of COVID-19 misinformation. The nonpartisan survey also found more than one third of those polled believe the US government is exaggeratin… Continue reading Majority of Americans believe at least some form of COVID misinformation

Next-gen supercharged COVID-19 vaccines may also target the common cold

UK researchers investigating a cohort of healthcare workers with a strange pre-existing resistance to SARS-CoV-2 infection have discovered a new antigen target for the next generation of COVID-19 vaccines. The researchers speculate the next wave of vac… Continue reading Next-gen supercharged COVID-19 vaccines may also target the common cold

Study compares decline in effectiveness of 3 COVID vaccines over time

A massive study comparing the real-world effectiveness of three COVID-19 vaccines over eight months has detected protection from infection may decline but protection from death holds strong. Tracking nearly 800,000 US Veterans, the study found Johnson … Continue reading Study compares decline in effectiveness of 3 COVID vaccines over time

Pfizer’s COVID-19 pill cuts hospitalization or death by nearly 90%

Pfizer’s experimental antiviral pill, developed to inhibit the replication of SARS-CoV-2 and prevent severe COVID-19, has shown extraordinary efficacy in the first data from a large Phase 2/3 clinical trial. The results, yet to be published in a peer-r… Continue reading Pfizer’s COVID-19 pill cuts hospitalization or death by nearly 90%